The diabetes and weight loss medication Ozempic, along with its counterpart Wegovy, has been the subject of growing legal scrutiny in recent years. Manufactured by Novo Nordisk, these drugs containing the active ingredient semaglutide have been linked to a range of potential side effects, including debilitating gastrointestinal issues. Now, a groundbreaking new study has uncovered an even more alarming potential risk – a significantly elevated likelihood of developing a devastating eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION), which can lead to sudden and irreversible vision loss.
The Rise of Ozempic Lawsuits
As more individuals have experienced adverse health outcomes after using Ozempic and Wegovy, a surge of litigation has emerged against Novo Nordisk. Industry experts previously estimated the total number of federal lawsuits involving these semaglutide-based drugs could reach 10,000 before the litigation concludes. However, emerging research linking Ozempic to possible vision loss risks has led some to believe the final figure may be even higher.
JAMA Study Linking Semaglutide to Vision Loss
In July 2024, the prestigious Journal of the American Medical Association (JAMA) published an article that raised new concerns about the potential risk of Ozempic side effects. The study, led by a team of researchers from Harvard Medical School, analyzed data from nearly 17,000 patients evaluated by neuro-ophthalmologists over a six-year period.
The researchers specifically focused on a subset of 1,700 patients who either had type 2 diabetes, were overweight, or had obesity. Within this group, they compared the incidence of non-arteritic anterior ischemic optic neuropathy (NAION) among patients prescribed the semaglutide-containing drugs Ozempic and Wegovy, versus those given non-semaglutide GLP-1 receptor agonist medications.
The results were staggering. In the diabetes patient group, 8.9% of those taking semaglutide (Ozempic/Wegovy) developed NAION, compared to just 1.8% of those on other medications. For the overweight/obesity group, the NAION rate was 6.7% among semaglutide users, versus only 0.8% in the non-semaglutide cohort.
What is NAION?
NAION is a serious eye disorder that affects the optic nerve – the bundle of fibers that transmits visual information from the eye to the brain. In people with NAION, the blood supply to the optic nerve is suddenly reduced or blocked, leading to optic nerve damage and rapid, painless vision loss, often in just one eye.
NAION is considered the second most common optic nerve disease in the United States, affecting an estimated 2-10 out of every 100,000 people annually. The condition is irreversible, with no known effective treatments, making it one of the leading causes of sudden, permanent blindness in middle-aged and older adults.
Implications for Ozempic and Wegovy Users
The implications of this new JAMA study are significant for the millions of Americans currently taking Ozempic, Wegovy, and other semaglutide-based medications. Patients with diabetes, those who are overweight, and those experiencing obesity who are prescribed these drugs may face an elevated risk of developing NAION and suffering sudden, irreversible vision loss.
This potential Ozempic side effect risk should prompt discussions between patients and their healthcare providers. Individuals with pre-existing optic nerve problems, significant visual impairment from other causes, or other known risk factors for NAION may need to carefully reconsider the potential benefits and risks of semaglutide treatment.
The Expanding Ozempic Litigation
The revelations from this JAMA study could have significant legal ramifications for Novo Nordisk, the manufacturer of Ozempic and Wegovy. The company’s alleged failure to adequately warn about the risk of severe vision complications like NAION may expose the company to a new wave of product liability lawsuits from former users who have suffered sudden and irreversible vision loss.
This adds to the growing body of evidence suggesting that Novo Nordisk prioritized profits over consumer safety when it came to disclosing the full range of potential side effects associated with these blockbuster diabetes and weight loss medications. Previous lawsuits have already alleged the company downplayed the potential risk of debilitating gastrointestinal issues like gastroparesis or stomach paralysis among Ozempic and Wegovy users.
Ozempic Lawsuit Information
Ozempic Gastroparesis Lawsuits, Leading Justice
